Nanjing Vazyme Biotech Co Ltd
SSE:688105
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.96
32.46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Nanjing Vazyme Biotech Co Ltd
Cost of Revenue
Nanjing Vazyme Biotech Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nanjing Vazyme Biotech Co Ltd
SSE:688105
|
Cost of Revenue
-¥514.9m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cost of Revenue
-¥2.7B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Cost of Revenue
-¥1.3B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-100%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cost of Revenue
-¥992.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cost of Revenue
-¥27.3B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-57%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cost of Revenue
-¥140.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Nanjing Vazyme Biotech Co Ltd
Glance View
Nanjing Vazyme Biotech Co., Ltd. is an intriguing player in the biotechnology sector, having carved a niche in the research, development, and production of an array of innovative biological reagents and solutions. Established in the vibrant city of Nanjing, this company stands at the crossroads of science and commerce, offering products that span across PCR reagents, protein engineering, and enzyme solutions. Their expertise is rooted in leveraging cutting-edge molecular biology, allowing the company to cater to a diverse clientele that includes academic research institutions, healthcare providers, and industries that require precise biochemical testing and analysis. Vazyme's growth story is intertwined with the fields of molecular diagnostics and life sciences, industries that have seen rapid advancements and heightened demand, especially in recent years. The company generates revenue predominantly through the sale of high-quality reagents that are essential for the accurate and reliable processing of biological data. By continually incorporating the latest scientific breakthroughs into their products, they ensure that their solutions remain at the forefront of the market. This strategy not only enhances their competitive edge but also solidifies customer loyalty and expands their market presence across the globe, establishing Vazyme as a key contributor to the biotechnology landscape.
See Also
What is Nanjing Vazyme Biotech Co Ltd's Cost of Revenue?
Cost of Revenue
-514.9m
CNY
Based on the financial report for Dec 31, 2023, Nanjing Vazyme Biotech Co Ltd's Cost of Revenue amounts to -514.9m CNY.
What is Nanjing Vazyme Biotech Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-76%
Over the last year, the Cost of Revenue growth was 63%. The average annual Cost of Revenue growth rates for Nanjing Vazyme Biotech Co Ltd have been -41% over the past three years , -76% over the past five years .
You don't have any saved screeners yet
